8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements

AbbVie files Form 8‑K dated Feb 4, 2026: furnishes press release (Exhibit 99.1) pursuant to Item 2.02;…

Filed with the SEC on February 4, 2026 · Summarized by InvestorsBot

AbbVie files Form 8‑K dated Feb 4, 2026: furnishes press release (Exhibit 99.1) pursuant to Item 2.02; cover page in Inline XBRL (Exhibit 104). Report signed by CFO Scott T. Reents. $ABBV 📄 #8K #SECfiling

Investors: review Exhibit 99.1 (press release dated Feb 4, 2026) filed under Item 2.02 for the company's results/operational update. Document available via SEC/AbbVie filings. $ABBV 🔍 #investing #earnings

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from AbbVie Inc.

AbbVie 8-K (Item 9.01) — Supplemental Indenture No.

8-K · March 4, 2026

On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…

8-K · March 4, 2026

AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among…

8-K · February 26, 2026

AbbVie ($ABBV) 2/24/26 agreed to sell $8.0B of senior notes across seven tranches (2028–2066); pricing…

8-K · February 26, 2026

AbbVie ($ABBV) issued a press release on Feb 4, 2026 announcing Q4 & FY 2025 financial results.

8-K · February 4, 2026

AbbVie filed an 8‑K on Jan 7, 2026.

8-K · January 7, 2026